Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1641Carcinoma, Renal Cell 504Urinary Bladder Neoplasms 462Carcinoma, Transitional Cell 234Breast Neoplasms 228Kidney Neoplasms 217Neoplasms 194Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 172Ovarian Neoplasms 163Melanoma 162Neoplasm Metastasis 143Lung Neoplasms 128Non-Muscle Invasive Bladder Neoplasms 107Pancreatic Neoplasms 103Stomach Neoplasms 101Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 84Carcinoma, Hepatocellular 77Sarcoma 75Esophageal Neoplasms 72Head and Neck Neoplasms 70Triple Negative Breast Neoplasms 67Adenocarcinoma 66Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Urologic Neoplasms 46Wilms Tumor 45

Interventions

enfortumab vedotin 2pembrolizumab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Advanced Bladder Cancer × Genitourinary × 1 year × Clear all
NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
41 enrolled
Genitourinary

Advanced Bladder Cancer

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting
224 enrolled
Genitourinary

Advanced Bladder Cancer

NCT07204496 2025-10-02

γδ-T-BLADDER

Shanghai 10th People's Hospital

Not yet recruiting
20 enrolled
Genitourinary

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡